NFA
SNNA

Nationwide Fund Advisors’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Nationwide Fund Advisors’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,936
Closed -$43K – 2745
2017
Q3 		$43K Buy
+1,936
New +$42.5K ﹤0.01% 3058

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nationwide Fund Advisors's SNNA Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2017, closing a stake of 1,936 shares — an estimated $43K sold.

Nationwide Fund Advisors first reported a position in SNNA in Q3 2017 and held it in 1 quarter. The position peaked at $43K in Q3 2017. 43 funds tracked by Wall St. Rank hold SNNA as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 1,936 Sienna Biopharmaceuticals, Inc. shares in Q4 2017, an estimated $43K.
  • Nationwide Fund Advisors first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • Nationwide Fund Advisors's Sienna Biopharmaceuticals, Inc. position peaked at $43K in Q3 2017.
  • 43 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.